50
Kronik Hepatit B
temlerle konulabilir. Tedavi kararı verilirken hastanın ve hastalığın progresyonu
dönemsel olarak değerlendirilmeli ve sürekli izlem yapılmalıdır.
Kaynaklar
1.
Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point
of view). Clinics and Research in Hepatology and Gastroenterology 2011; 35:
813—18
2.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology
2009;50:661—2.
3.
Chen M, Sallberg M, Hughes J, et al. Immune tolerance split between hepatitis B
virus precore and core proteins. J Virol. 2005;79:3016-3027.
4.
Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in
the immunotolerant phase of infection: histologic findings and outcome. Clin
Gastroenterol Hepatol 2007;5:636—41.
5.
Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in
Chinese chronic hepatitis B patients in immunetolerant phase. Hepatology
2007;46:395—401.
6.
Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum
alanine aminotransferase levels. Ann Intern Med 2002;137:1—10.
7.
Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic
hepatitis B virus-infected asymptomatic patients with persistently normal ALT.
Gastroenterology 2008;134:1376—84.
8.
Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with
chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007;5:921—31.
9.
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a
biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65—
73.
10.
European Association for the Study of the Liver. EASL Clinical Practice
Guidelines: Management of chronic hepatitis B virus infection. Journal of
Hepatology 2012; 57: 167–85
11.
Sharma SK, Saini N, Chwla Y. Hepatitis B virus: Inactive carriers. Virology Journal
2005; 2:82-7
12.
Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa
treatment in Chinese patients with chronic hepatitis B infection: the effect on
hepatitis B e antigen seroconversion and the development of cirrhosis-related
complications. Hepatology 2001; 34:139-45.
13.
McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes
of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med
2001; 135:759-68.
14.
Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:1225-41.
15.
Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and
treatment. Semin Liver Dis. 2006 May;26(2):142-52.
16.
Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions
with biochemical markers in patients with chronic hepatitis. J Hepatol
2003;39:222—30.
